Krista Qualmann on Genetic Counseling and Testing for Patients with Cancer

Video

Krista Qualmann discusses hereditary cancer syndromes.

Krista Qualmann, MS, CGC, Memorial Hermann Mischer Neuroscience Institute at the Texas Medical Center and UTHealth, discusses hereditary cancer syndromes.

About 5% to 10% of cancers are caused by single-gene disorders. These hereditary cancer syndromes are most well-known for causing cancers such as breast cancer, ovarian cancer and endometrial cancer. They can also have a hand in colon cancer, brain tumors and melanoma.

Related Videos
Testi
Patrick Buxton, RN, BSN
Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic Tests
Elizabeth Aronson
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
Related Content
breast cancer

Managing Brain Metastases in a Patient With HER+ Breast Cancer

December 4th 2023
Article

Stephanie L. Graff, MD, FACP; Christine McGinn, MSN, APRN, ACNP-BC; and Jeanine Showalter, MSN, APRN, FNP-BC, AOCNP, share how they approach treatment decision-making following a brain metastasis.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

breast cancer

Biosimilars Make Routine Prophylaxis With G-CSF Feasible in HER2+ Breast Cancer

December 1st 2023
Article

The increasing use of biosimilars makes prophylaxis with growth factor more cost effective.

The Vitals

Jacki Garcia and Kristin Hendrickson on Navigating Patients Through Phase 0 Trials

July 15th 2023
Podcast

Jacki Garcia, RN, BSN, CNRN; and Kristin Hendrickson, BA, RN, discuss phase 0 trials and how they can help expedite the research process for brain cancer therapies.

ovarian cancer

Olaparib Misses Mark in Recurrent Platinum-Sensitive Ovarian Cancer

November 25th 2023
Article

Olaparib did not significantly improve overall survival compared with chemotherapy in recurrent, platinum-sensitive ovarian cancer.

Endometrial Cancer

Patients With Endometrial Cancer Report Maintained HRQOL With Dostarlimab

November 21st 2023
Article

Those receiving dostarlimab experienced numerical improvements from baseline in terms of quality of life, emotional functioning, pain, and back and pelvis pain scores.

© 2023 MJH Life Sciences

All rights reserved.